



ASX/MEDIA RELEASE

7 May 2018

Adjournment of shareholder meeting

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) refers to its announcement on 4 May regarding the receipt of an unsolicited non-binding, indicative and conditional proposal from CDH Investments (**Indicative Proposal**) and its intention to apply to the Court to seek a postponement of the Scheme Meeting scheduled to occur on Monday, 7 May 2018.

Sirtex announces that the Federal Court on Friday made orders postponing the Scheme Meeting to a date to be determined.

Sirtex will make a further announcement about the proposed date, time and location of the postponed Scheme Meeting in due course.

- ENDS -

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406